(17 alpha-acetoxy-6-chloro-2-oxa-4, 6-pregnadiene-3, 20-dione).
New antiandrogen with steroid structure.
Mechanism:
Inhibit 5 alpha-dihydrotestosterone (5-alpha-DHT) and testosterone receptors activity by blocking androgen receptors and in this way decreasing the nuclear androgen receptors fraction. Also, series of in vivo studies demonstrated that TZP-4238 inhibited the uptake of testosterone and the decrease of DHT and testosterone.
Powerful new receptor inhibitor.
It can be used topically.
TZP-4238 hasn't been tested on androgenetic alopecia model. |
|
|
|
